Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 7;30(14):1716-26.
doi: 10.1038/onc.2010.550. Epub 2010 Dec 6.

GNL3L depletion destabilizes MDM2 and induces p53-dependent G2/M arrest

Affiliations

GNL3L depletion destabilizes MDM2 and induces p53-dependent G2/M arrest

L Meng et al. Oncogene. .

Abstract

Guanine nucleotide binding protein-like 3-like (GNL3L) is a nucleolar protein and the vertebrate paralogue of nucleostemin (NS). We previously reported that nucleoplasmic mobilization of NS stabilizes MDM2 (mouse double minute 2). Here, we investigated the role of GNL3L as a novel MDM2 regulator. We found that GNL3L binds MDM2 in vivo and displays the same function as NS in stabilizing MDM2 protein and preventing its ubiquitylation. The interaction between GNL3L and MDM2 also takes place in the nucleoplasm. However, the MDM2 regulatory activity of GNL3L occurs constitutively and does not so much depend on the nucleolar release mechanism as NS does. GNL3L depletion triggers G2/M arrest in the p53-wild-type HCT116 cells more than in the p53-null cells, and upregulates specific p53 targets (that is, Bax, 14-3-3σ and p21) without affecting the ubiquitylation or stability of p53 proteins. The inhibitory activity of GNL3L on p53-mediated transcription correlates with the increased expression of GNL3L and reduced expression of 14-3-3σ and p21 in human gastrointestinal tumors. This work shows that in contrast to most nucleolar proteins that negatively control MDM2, GNL3L and NS are the only two that are designed to stabilize MDM2 protein under basal or induced condition, respectively, and may act as tumor-promoting genes.

PubMed Disclaimer

Figures

Figure 1
Figure 1. GNL3L competes against NS for MDM2 binding
(a) MDM2 (Myc) and NS family proteins (HA) were co-immunoprecipitated (coIP) and immunoblotted (IB) by anti-tag antibodies in HEK293 cells. The results showed that MDM2 preferentially interacts with NS and GNL3L. (b) Endogenous binding between MDM2 and GNL3L was demonstrated by anti-MDM2 (left panel) and anti-GNL3L (right panel) coIP experiments. IgG and preimmune serum (pre-I) precipitated samples were used as controls. (c) Anti-FLAG coIP of GNL3L (HA), NS (Myc), and MDM2 (FLAG) showed that GNL3L and NS compete against each other for MDM2 binding. By comparison, GNL3L shows more binding with MDM2 than wild-type NS does (left panel) and less binding with MDM2 than NS-G256V does (right panel). NS-G256V is a nucleoplasm-mislocalized mutant of NS (Fig. S1b3). (d) Triple coIP of GNL3L (HA), MDM2 (FLAG), and p53 (Myc) by anti-HA (left panel) or anti-Myc antibody (right panel) shows that GNL3L may bind p53 indirectly through MDM2.
Figure 2
Figure 2. GNL3L binds the central domain of MDM2 via its GTP-binding or intermediate domain
Diagrams show MDM2 (a1) and GNL3L single (b1) or multi-domain (c1) deletion mutants. Grey lines and numbers indicate the deleted regions and amino acid positions. Abbreviations: N, p53-binding; I1 and I2, intermediate-1 and -2; AZ, acidic-zinc finger; R, RING-finger; B, basic; C, coiled-coil; G, GTP-binding; and I, intermediate. CoIP showed that binding between GNL3L and MDM2 requires the I1, AZ, and I2 domains of MDM2 (a2) and the G- or I-domain of GNL3L (b2, c2, and c3).
Figure 3
Figure 3. GNL3L stabilizes MDM2 protein by preventing its ubiquitylation
(a) Transient siRNA knockdown of GNL3L (siG3-2) in HeLa cells decreases the level of endogenous MDM2 proteins. This effect can be reversed by coexpression of a siG3-2-resistant GNL3L, G3L-siR. (b) Coexpression of GNL3L (HA) increases the protein level of endogenous MDM2 in a dose-dependent manner. (c) The effect of GNL3L on MDM2 protein stability was determined in H1299 cells transfected with MDM2 alone (Ctrl) or cotransfected with MDM2 and GNL3L (G3L). After cycloheximide treatment, the MDM2 protein amounts were measured, adjusted by their α-tubulin amounts, and expressed as percentages of the MDM2 protein amount at the 0h time-point (bottom). (d) The cycloheximide experiment showed that GNL3L knockdown in HCT116-8 cells significantly reduces the protein stability of endogenous MDM2 (n=3, p<0.005, Repeated Measures ANOVA) without affecting the stability of endogenous p53 (p=0.27). (e) HEK293 cells were transfected with the (His)6-tagged ubiquitin, MDM2 and a control (shScr) or GNL3L-specific (shG3-a) shRNAmir construct. Ubiquitylated MDM2 products were precipitated by Ni2+ sepharose (His PD) and detected by anti-MDM2 antibody. GNL3L depletion increases the ubiquitylation of MDM2, and this effect can be rescued by an shRNA-resistant GNL3L (G3L-shR). (f) Overexpression of wild-type GNL3L decreases MDM2 polyubiquitylation compared to the control sample. (g) GNL3L knockdown (left panel) or overexpression (right panel) has no effect on the MDM2-induced p53 ubiquitylation.
Figure 4
Figure 4. GNL3L colocalizes with MDM2 in the nucleoplasm. Knockdown of GNL3L increases the nucleolar-nucleoplasmic exchange rate of MDM2
(a) Confocal studies showed that GFP-fused GNL3L and FLAG-tagged MDM2 colocalize in the nucleoplasm of HCT116-8 cells and that coexpression of these two proteins does not change each other's distributions. Anti-fibrillarin staining labels the nucleolus in singly transfected cells. Bars show 5um. (b1) The exchange rate between the nucleolar and nucleoplasmic pools of MDM2 was measured in HCT116-8 cells by FLIP (fluorescence loss in photobleaching). The nucleolar signal of GFP-fused MDM2 was bleached repeatedly (circle) and the nucleoplasmic signal was recorded (rectangle). Time-sequenced images and their time intervals (in seconds) to the first bleaching pulse were shown. (b2) Knockdown of GNL3L (G3L-KD, in red) significantly increases the nucleolar-nucleoplasmic exchange rate of MDM2 (p < 0.01). (b3) Overexperssion of GNL3L exerts only a small effect on decreasing the exchange rate of MDM2 (p = 0.05). Error bars represent s.e.m. shown in one direction (arrows in graph). Y-axis represents the relative fluorescence index (RFI). Top arrows indicate bleaching pulses.
Figure 5
Figure 5. The activity of GNL3L in regulating MDM2 ubiquitylation is constitutively active and less controlled by the nucleolar release mechanism than NS is
(a) For in vivo ubiquitylation assays, HEK293 cells were transfected with the (His)6- tagged ubiquitin, MDM2 (Myc), and GNL3L or NS-specific shRNA constructs. GNL3L knockdown shows a stronger effect in increasing MDM2 ubiquitylation than NS does. (b) The effects of GNL3L and NS overexpression on MDM2 ubiquitylation were compared using the same assay. Overexpression of wild-type and nucleoplasmic forms (G3L-dB and G3L-G253V) of GNL3L shows the same effect in decreasing the ubiquitylation of MDM2. On the other hand, nucleoplasmic forms of NS (NS-dB and NS-G256V) show much stronger effects compared not only to wild-type NS but also to wild-type and mutant GNL3L. (c) Endogenous coIP of MDM2 and GNL3L (or NS) showed that mitosis increases the coIP efficiency of NS and MDM2 more than it does on the coIP of GNL3L and MDM2.
Figure 6
Figure 6. GNL3L knockdown triggers G2/M arrest and p53 activation
(a) The cell cycle phenotypes of control (siScr) and GNL3L (siG3L) knockdown were analyzed by propidium-iodide-labeled flow cytometry in HCT116-8 (p53+/+) and HCT116-2 (p53−/−) cells. GNL3L knockdown triggers G2/M arrest more in the p53+/+ cells than in the p53−/− cells. (b) Western blots confirm GNL3L knockdown efficiencies and reveal a slight decrease of MDM2 proteins in the p53-wild-type and null cells and an increase of phospho-Cdc2 (Y15) in the p53-wild-type cells by GNL3L knockdown. (c) The GNL3L knockdown effect on the p53 activity was determined by quantitative RT-PCR assays of several p53 downstream targets. GNL3L depletion up-regulates Bax, 14-3-3-σ, and p21 in a p53-dependent manner. *, p < 0.01; **, p < 0.001; ***, p < 0.0001.
Figure 7
Figure 7. NS depletion triggers a compensatory up-regulation of GNL3L in HCT116 and U2OS cells
(a1) qRT-PCR measurements revealed a compensatory up-regulation of GNL3L transcripts following NS knockdown in p53-wild-type and null HCT116 cells and U2OS cells but not in HeLa or HEK293 cells. Conversely, GNL3L knockdown shows no such effect on NS. (a2) The increase of GNL3L expression by NS knockdown was confirmed by western blots. (b) Mycophenolic acid (MPA) treatment triggers a reciprocal increase of GNL3L and decrease of NS in HCT116-8 and 2 cells. The MPA-induced GNL3L up-regulation can be reversed by MG132 treatment but not by NS overexpression. (c) GNL3L can functionally rescue the MDM2 ubiquitylation phenotype of NS-knockdown cells. (d) GNL3L and NS form a complex regulatory network on the MDM2-p53 pathway. Both proteins show similar activities in MDM2 stabilization but differ in their modes of regulation. Multiple points of feedback and cross-regulation exist. Arrows and X’s indicate excitatory or inhibitory functions, respectively, and the dashed line represents an event regulated by the nucleolar release mechanism.
Figure 8
Figure 8. Correlation between GNL3L expression and p53 activities in human cancers
Nine types of human cancers show a significant percentage of samples with increased GNL3L expression. Among them, the colorectal, gastric, and esophageal carcinomas also show a down-regulation of 14-3-3σ and p21. Bax expression is increased in most tumors. Y-axis represents the percentage of tumor samples whose expression of the target gene is 1.5-fold higher (grey bars) or lower (black bars) than that of normal tissues.

Similar articles

Cited by

References

    1. Baddoo M, Hill K, Wilkinson R, Gaupp D, Hughes C, Kopen GC, Phinney DG. J Cell Biochem. 2003;89:1235–49. - PubMed
    1. Beekman C, Nichane M, De Clercq S, Maetens M, Floss T, Wurst W, Bellefroid E, Marine JC. Mol Cell Biol. 2006;26:9291–301. - PMC - PubMed
    1. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Science. 1998;282:1497–501. - PubMed
    1. Dai MS, Sun XX, Lu H. Mol Cell Biol. 2008;28:4365–76. - PMC - PubMed
    1. Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. Mol Cell Biol. 2004;24:7654–68. - PMC - PubMed

Publication types

MeSH terms